119-HR-8160 Journalist Public Summary

Headline Summary

A House bill would ramp up federal research, public awareness, and clinician training on premenstrual dysphoric disorder (PMDD) to improve diagnosis and treatment access.

What It Does

The bill directs federal health agencies to study PMDD more deeply, run a national awareness campaign, and fund training programs so frontline clinicians can better recognize and treat the condition. In short: more evidence, more public and provider awareness, and more trained professionals.

• NIH research push: Expands studies on PMDD’s causes, diagnosis, and treatment; supports clinical trials; and improves representation of diverse populations (FY 2027–2031 authorizations).
• National awareness and education: HHS would run a public campaign on symptoms, treatment options, and stigma reduction; HRSA would develop continuing education so providers can accurately diagnose and offer evidence‑based care (FY 2026–2030 authorizations).
• Workforce training grants: Funds new or expanded training (residencies, fellowships, CME) for physicians, nurses, pharmacists, and other clinicians to improve PMDD care; also supports training tied to mid‑life women’s health, perimenopause, and menopause (FY 2027–2031 authorizations).
• Progress report: HHS must report to Congress within two years of enactment on research, awareness, and treatment access gains.

Why it matters: PMDD is a severe, cyclical mood disorder recognized in DSM‑5 that can seriously disrupt work, school, and daily life. Estimates suggest roughly 2–5% of people who menstruate meet criteria, so better training and awareness could reduce underdiagnosis and speed treatment. (ncbi.nlm.nih.gov)

Who’s For It

• Primary sponsor and co-sponsors: Introduced in the House on March 30, 2026 by Rep. Yassamin Ansari (D‑AZ), with a coalition of co‑sponsors listed in the bill text. Their stated aim is to close research gaps, reduce stigma, and improve access to accurate diagnosis and treatment.
• Public health and patient advocates: Groups focused on menstrual and women’s mental health typically support efforts that increase research funding, provider education, and public awareness (consistent with the bill’s findings).

Who’s Against It

• No formal opposition noted yet (the bill was just introduced).
• Potential concerns lawmakers may raise:
• - Cost and open‑ended authorizations (“such sums as necessary”) and whether appropriators will fund at requested levels.
• - Possible overlap with existing HHS programs; demands for clearer coordination and outcome metrics.
• - Federal role in shaping continuing medical education content and ensuring scientific neutrality.

What’s Next

Status as of March 31, 2026: H.R. 8160 has been referred to the House Energy and Commerce Committee. Next typical steps are a hearing and a committee “markup” session; if approved, the bill would move to a full House vote, then to the Senate, and finally to the President if both chambers pass it. Energy and Commerce has jurisdiction over public health and NIH matters, which is why health research and education bills often go there. (house.gov)